|Hoyoung Huh, M.D., PH.D.|
Hoyoung Huh, M.D., Ph.D., is the chairman of Geron Corporation, where he has also held executive chairman and director positions, and is on the board of directors for Addex Pharmaceuticals. Dr. Huh has been involved in the formation, management and financing of more than 20 successful entities across the United States, Europe and Asia. He was previously the president, chief executive officer and chairman of BiPar Sciences Inc., which was acquired by Sanofi-aventis in 2009. Prior to that, he served as the chairman of Epizyme Inc., chief operating officer and board member of Nektar Therapeutics and board member of Facet Biotech, which was acquired by Abbott Laboratories in 2010. Dr. Huh was formerly a partner at McKinsey & Company in the healthcare and technology practices. Dr. Huh holds a B.S. in biochemistry from Dartmouth College, an M.D. from Cornell University Medical College, and a Ph.D. in genetics and cell biology from Cornell University/Sloan-Kettering Institute.
|Sean McCarthy, D. Phil.|
President and Chief Executive Officer
Sean McCarthy, D. Phil, joined CytomX in 2011 and has more than twenty years of experience in the biotechnology industry encompassing roles in R&D management, business development and financing. Following completion of his post-doctoral training at the DNAX Research Institute (now Merck Palo Alto) Dr. McCarthy held research leadership and program management roles at Millennium Pharmaceuticals where he managed therapeutic protein discovery programs. From Millennium he joined SGX Pharmaceuticals where he spearheaded a wide range of pharma partnerships as vice president, business development. He also served on the SGX management team that led a successful initial public offering in 2006 (SGXP; subsequently acquired by Lilly). Prior to joining CytomX Dr. McCarthy was a transactional partner at Pappas Ventures responsible for investments in therapeutic, medical device and molecular diagnostic companies including LEAD Therapeutics (acquired by Biomarin), TyRx (acquired by Medtronic), Lumena (acquired by Shire). Dr. McCarthy is an author on multiple peer-reviewed scientific publications, issued patents and filed patent applications. He received his B.Sc. in biochemistry and pharmacology at King’s College, University of London; his M.B.A. from the Rady School of Management at University of California, San Diego; and a D. Phil. in cancer biology from St. John’s College, University of Oxford. Dr. McCarthy is a Board member of the California Life Sciences Association.
Neil Exter joined Third Rock Ventures in 2007 and plays an integral role in the overall formation, development and business strategy of its portfolio companies. Mr. Exter has more than 17 years of business development and strategic experience, facilitating the successful development and implementation of operations and collaborations across the spectrum of newly emerging and established biotech companies. Prior to joining Third Rock Ventures, Mr. Exter was the chief business officer of Alantos Pharmaceuticals, leading the sale of the company to Amgen, and vice president of Millennium Pharmaceuticals, directing in-licensing and M&A. Earlier in his career, he held various executive management roles within the high technology industry, including tenures at Hewlett Packard and Wang Laboratories. Mr. Exter is a member of the board of overseers and the board research committee at Children’s Hospital Boston. Additionally, he is a member of the Innovation Research Fund at Partners Healthcare and the advisory council of the Electrical and Computer Engineering Department at Cornell. Mr. Exter received his B.S. from Cornell University, M.S. from Stanford University and M.B.A. as a Baker Scholar from Harvard Business School.
Fred Gluck is a former managing partner (chief executive) of McKinsey & Company Inc. After retiring from McKinsey in 1995, he joined the Bechtel Group, where he served as vice chairman and director. He later rejoined McKinsey & Company as a consultant until retiring again in July 2003. Mr. Gluck was the founding chairman and CEO of both CytomX and Cynvenio Biosystems and continues to serve as chairman of Cynvenio. He also serves as director of a number of eleemosynary organizations, including the Foundation Board of the University of California, Santa Barbara, the Kavli Institute of Theoretical Physics and The New York Presbyterian Hospital (Emeritus). He recently retired from the Board of Amgen and was the presiding director of HCA (Hospital Corporation of America). Mr. Gluck received his B.S. from Manhattan College and an M.S. from New York University: both degrees in electrical engineering.
|Tim Shannon, M.D.|
Tim Shannon, M.D., joined Canaan Partners as a venture partner in 2009, bringing extensive biopharmaceutical operational experience leading product and business development and his experience as a practicing physician in pulmonary and critical care medicine. His strategic business sense as well as his hands-on medical and patient care perspective adds a unique approach to Canaan’s investments in biopharmaceuticals. Dr. Shannon was previously president and chief executive officer of CuraGen, a biopharmaceutical company focused on oncology. Prior to CuraGen, he held positions of increasing responsibility for Bayer’s Pharmaceutical Business Group, including senior vice president of global medical development. He is a director at Celldex Therapeutics, which acquired CuraGen in October 2009, and is a member of the Quality Assurance, Compliance and Safety Committee for The Yale Cancer Center. In addition to his operational experience, he was assistant professor of the pulmonary and critical care division at Yale University School of Medicine and an attending physician in pulmonary and critical care medicine at the West Haven V.A. Medical Center. Dr. Shannon received his post graduate medical training at the Beth Israel Hospital of Harvard Medical School and at Boston University, and earned his medical degree from the University of Connecticut. He holds a B.A. in chemistry from Amherst College.
Matthew P. Young was appointed executive vice president and chief financial officer of Jazz Pharmaceuticals in February 2015. He previously had served as senior vice president and chief financial officer of Jazz since March 2014 and as senior vice president, corporate development of Jazz since April 2013. Prior to joining Jazz, Mr. Young worked in investment banking for approximately 20 years. From February 2009 to April 2013, he served as a managing director in global healthcare of Barclays Capital Inc., an investment banking firm, where his role included acting as the co-head of life sciences at Barclays Capital. From 2007 to 2008, Mr. Young served as a managing director of Citigroup Global Markets Inc., an investment banking firm, and from 2003 to 2007, as a managing director of Lehman Brothers Inc., an investment banking firm. In 2015, he joined the board of directors of PRA Health Sciences Inc., a contract research company. Mr. Young received a B.S. in economics and a M.B.A. from the Wharton School of the University of Pennsylvania.
|John Scarlett, M.D.|
|John “Chip” A. Scarlett currently serves as chief executive officer, president and a member of the board of directors of Geron Corporation. Since February 2015, Dr. Scarlett has also served as a member of the board of directors of Chiasma, Inc. Prior to joining Geron in 2011, Dr. Scarlett served as president, chief executive officer and a member of the board of directors of Proteolix, Inc., from February 2009 until its acquisition by Onyx Pharmaceuticals, Inc., in November 2009. From February 2002 until its acquisition by Ipsen, S.A., in October 2008, Dr. Scarlett served as founder, chief executive officer and a member of the board of directors of Tercica, Inc., and also as its president from February 2002 through February 2007. From March 1993 to May 2001, Dr. Scarlett served as president and chief executive officer of Sensus Drug Development Corporation. In 1995, he co-founded Covance Biotechnology Services, Inc., and served as a member of its board of directors from inception to 2000. From 1991 to 1993, Dr. Scarlett headed the North American Clinical Development Center and served as senior vice president of medical and scientific affairs at Novo Nordisk Pharmaceuticals, Inc. Dr. Scarlett holds a B.A. in chemistry from Earlham College and an M.D. from the University of Chicago, Pritzker School of Medicine.|